Ozempic · Wegovy · Zepbound · Mounjaro

GLP-1 questions, answered from the trials

Plain-language answers to the 35 questions GLP-1 users ask most, built from the prescribing labels, clinical trials and guidelines. Every number links to where it came from.

Education, not medical advice. No supplements, no sponsors, no affiliate links. Decisions about your prescription belong with your prescriber.

The number most articles leave out

Nausea on Wegovy 2.4 mgpooled trials, US label
44%
16% placebo
Stopped for gut side effectspooled STEP 1 to 3
4.3%
0.7% placebo

Side effects are common; stopping because of them is not. Every side effect, drug vs placebo.

236 linked sourcesLabels, trials and guidelines, each graded
Placebo shownEvery rate next to its placebo rate
Honest gapsPages say when nobody has studied it
Questions to askEach page ends with prescriber questions

Three things the trials show

8 days

Median length of a nausea episode on semaglutide. Constipation lasted far longer, a median of 47 days. Timelines

14%

Weight regained in a year by people switched from tirzepatide to placebo in SURMOUNT-4. Stopping

About 1 in 4

Share of weight lost that was lean mass on tirzepatide (26%), about the same as on placebo (25%). Lean mass is not the same as muscle. Muscle loss

Sources: Wharton et al. 2022, pooled STEP 1 to 3 · Aronne et al. 2024, SURMOUNT-4 · Look et al. 2025, SURMOUNT-1 body composition. Hero figures: Wegovy US label and Wharton 2022.

On YouTube

Fewer Bites: the video side

Captioned Shorts and 4 to 6 minute explainers, each tied to a page here with its sources. Videos · Fewer Bites on YouTube